Viracta Therapeutics (VIRX) Stock Forecast, Price Target & Predictions
VIRX Stock Forecast
Viracta Therapeutics stock forecast is as follows: an average price target of $8.00 (represents a 3087.25% upside from VIRX’s last price of $0.25) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
VIRX Price Target
The average price target for Viracta Therapeutics (VIRX) is $8.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $8.00. This represents a potential 3087.25% upside from VIRX's last price of $0.25.
VIRX Analyst Ratings
According to 2 Wall Street analysts, Viracta Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for VIRX stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Viracta Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 11, 2022 | - | RBC Capital | $8.00 | $3.33 | 140.24% | 3087.25% |
The latest Viracta Therapeutics stock forecast, released on Nov 11, 2022 by RBC Capital company, set a price target of $8.00, which represents a 140.24% increase from the stock price at the time of the forecast ($3.33), and a 3087.25% increase from VIRX last price ($0.25).
Viracta Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.25 | $0.25 | $0.25 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Viracta Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Viracta Therapeutics's last price of $0.25. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 23, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Nov 11, 2022 | RBC Capital | Outperform | Outperform | Hold |
Viracta Therapeutics's last stock rating was published by Oppenheimer on May 23, 2024. The company gave VIRX a "Outperform" rating, the same as its previous rate.
Viracta Therapeutics Financial Forecast
Viracta Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 21 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $120.00K | $2.07M | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | $4.50M | $375.00K | $375.00K | $625.00K | $200.00K | $200.00K | $300.00K |
| High Forecast | - | - | - | - | - | - | - | $4.50M | $375.00K | $375.00K | $625.00K | $200.00K | $200.00K | $300.00K |
| Low Forecast | - | - | - | - | - | - | - | $4.50M | $375.00K | $375.00K | $625.00K | $200.00K | $200.00K | $300.00K |
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.32% | 3.32% | - | - | - |
Viracta Therapeutics's average Quarter revenue forecast for Jun 20 based on 0 analysts is $375.00K, with a low forecast of $375.00K, and a high forecast of $375.00K. VIRX's average Quarter revenue forecast represents a 212.50% increase compared to the company's last Quarter revenue of $120.00K (Mar 20).
Viracta Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 21 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | $-79.11M | $-6.33M | $-5.81M | $-5.29M | $-5.87M | $-6.13M | $-5.60M |
| Avg Forecast | - | - | - | - | - | - | - | $900.00K | $75.00K | $75.00K | $125.00K | $40.00K | $40.00K | $60.00K |
| High Forecast | - | - | - | - | - | - | - | $900.00K | $75.00K | $75.00K | $125.00K | $40.00K | $40.00K | $60.00K |
| Low Forecast | - | - | - | - | - | - | - | $900.00K | $75.00K | $75.00K | $125.00K | $40.00K | $40.00K | $60.00K |
| Surprise % | - | - | - | - | - | - | - | -87.90% | -84.33% | -77.49% | -42.34% | -146.73% | -153.20% | -93.28% |
undefined analysts predict VIRX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Viracta Therapeutics's previous annual EBITDA (undefined) of $NaN.
Viracta Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 21 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | $-79.62M | $-6.39M | $-7.09M | $-5.36M | $-6.01M | $-6.35M | $-6.12M |
| Avg Forecast | $-6.70M | $-6.70M | $-8.67M | $-8.28M | $-7.49M | $-10.51M | $-14.45M | $-1.63B | $-75.85M | $-96.54M | $-99.99M | $-117.23M | $-137.92M | $-237.91M |
| High Forecast | $-6.70M | $-6.70M | $-8.67M | $-8.28M | $-7.49M | $-10.51M | $-14.45M | $-1.30B | $-75.85M | $-96.54M | $-99.99M | $-117.23M | $-137.92M | $-237.91M |
| Low Forecast | $-6.70M | $-6.70M | $-8.67M | $-8.28M | $-7.49M | $-10.51M | $-14.45M | $-1.96B | $-75.85M | $-96.54M | $-99.99M | $-117.23M | $-137.92M | $-237.91M |
| Surprise % | - | - | - | - | - | - | - | 0.05% | 0.08% | 0.07% | 0.05% | 0.05% | 0.05% | 0.03% |
Viracta Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. VIRX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Viracta Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 21 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | $3.84M | $2.06M | $2.23M | $2.48M | $2.51M | $2.52M | $2.44M |
| Avg Forecast | - | - | - | - | - | - | - | $47.13M | $3.93M | $3.93M | $6.55M | $2.09M | $2.09M | $3.14M |
| High Forecast | - | - | - | - | - | - | - | $47.13M | $3.93M | $3.93M | $6.55M | $2.09M | $2.09M | $3.14M |
| Low Forecast | - | - | - | - | - | - | - | $47.13M | $3.93M | $3.93M | $6.55M | $2.09M | $2.09M | $3.14M |
| Surprise % | - | - | - | - | - | - | - | 0.08% | 0.53% | 0.57% | 0.38% | 1.20% | 1.20% | 0.78% |
Viracta Therapeutics's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to VIRX last annual SG&A of $3.84M (Mar 21).
Viracta Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 21 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | $-5.25 | $-0.17 | $-0.19 | $-0.48 | $-0.57 | $-0.88 | $-1.03 |
| Avg Forecast | $-0.17 | $-0.17 | $-0.22 | $-0.21 | $-0.19 | $-0.27 | $-0.37 | $0.02 | $-1.93 | $-2.45 | $-2.54 | $-2.98 | $-3.50 | $-6.04 |
| High Forecast | $-0.17 | $-0.17 | $-0.22 | $-0.21 | $-0.19 | $-0.27 | $-0.37 | $0.02 | $-1.93 | $-2.45 | $-2.54 | $-2.98 | $-3.50 | $-6.04 |
| Low Forecast | $-0.17 | $-0.17 | $-0.22 | $-0.21 | $-0.19 | $-0.27 | $-0.37 | $0.02 | $-1.93 | $-2.45 | $-2.54 | $-2.98 | $-3.50 | $-6.04 |
| Surprise % | - | - | - | - | - | - | - | -225.00% | 0.09% | 0.08% | 0.19% | 0.19% | 0.25% | 0.17% |
According to undefined Wall Street analysts, Viracta Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to VIRX previous annual EPS of $NaN (undefined).
Viracta Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SQZ | SQZ Bio | $0.44 | $400.00 | 90809.09% | Buy |
| VIRX | Viracta Therapeutics | $0.25 | $8.00 | 3100.00% | Buy |
| ALXO | ALX Oncology | $2.22 | $24.50 | 1003.60% | Buy |
| VINC | Vincerx Pharma | $0.70 | $4.00 | 471.43% | Buy |
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| CABA | Cabaletta Bio | $4.11 | $16.33 | 297.32% | Buy |
| TRVI | Trevi Therapeutics | $3.37 | $12.00 | 256.08% | Buy |
| EYPT | EyePoint Pharmaceuticals | $9.10 | $30.00 | 229.67% | Buy |
| BCYC | Bicycle Therapeutics | $27.02 | $70.50 | 160.92% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| STOK | Stoke Therapeutics | $14.47 | $33.75 | 133.24% | Buy |
| IGMS | IGM Biosciences | $12.30 | $25.00 | 103.25% | Buy |
| LPTX | Leap Therapeutics | $2.74 | $5.50 | 100.73% | Buy |
| LYRA | Lyra Therapeutics | $0.28 | $0.50 | 78.57% | Hold |
| BMEA | Biomea Fusion | $7.85 | $13.67 | 74.14% | Buy |
| MREO | Mereo BioPharma Group | $4.28 | $6.75 | 57.71% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
VIRX Forecast FAQ
Is Viracta Therapeutics a good buy?
Yes, according to 2 Wall Street analysts, Viracta Therapeutics (VIRX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of VIRX's total ratings.
What is VIRX's price target?
Viracta Therapeutics (VIRX) average price target is $8 with a range of $8 to $8, implying a 3087.25% from its last price of $0.251. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Viracta Therapeutics stock go up soon?
According to Wall Street analysts' prediction for VIRX stock, the company can go up by 3087.25% (from the last price of $0.251 to the average price target of $8), up by 3087.25% based on the highest stock price target, and up by 3087.25% based on the lowest stock price target.
Can Viracta Therapeutics stock reach $0?
VIRX's average twelve months analyst stock price target of $8 supports the claim that Viracta Therapeutics can reach $0 in the near future.
What are Viracta Therapeutics's analysts' financial forecasts?
Viracta Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-32.444M (high $-32.444M, low $-32.444M), average SG&A $0 (high $0, low $0), and average EPS is $-0.823 (high $-0.823, low $-0.823). VIRX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-30.342M (high $-30.342M, low $-30.342M), average SG&A $0 (high $0, low $0), and average EPS is $-0.77 (high $-0.77, low $-0.77).
Did the VIRX's actual financial results beat the analysts' financial forecasts?
Based on Viracta Therapeutics's last annual report (Dec 2019), the company's revenue was $2.07M, beating the average analysts forecast of $1.32M by 56.45%. Apple's EBITDA was $-22.886M, missing the average prediction of $265K by -8736.36%. The company's net income was $-23.844M, missing the average estimation of $-593M by -95.98%. Apple's SG&A was $9.95M, missing the average forecast of $13.88M by -28.31%. Lastly, the company's EPS was $-2.74, missing the average prediction of $-15.05 by -81.79%. In terms of the last quarterly report (Mar 2020), Viracta Therapeutics's revenue was $120K, missing the average analysts' forecast of $375K by -68.00%. The company's EBITDA was $-5.812M, missing the average prediction of $75K by -7849.44%. Viracta Therapeutics's net income was $-7.093M, missing the average estimation of $-96.542M by -92.65%. The company's SG&A was $2.23M, missing the average forecast of $3.93M by -43.27%. Lastly, the company's EPS was $-0.19, missing the average prediction of $-2.45 by -92.24%